News

MedImmune and NIST have inked a five-year agreement to this effect. As per the terms of the agreement, MedImmune is providing first-year funding for seven NIST postdoctoral scientists,

The company estimates the FDA decision for the sNDA in June 2015 based on the anticipated Prescription Drug User Fee Act (PDUFA) action date. Pfizer Global Innovative Pharmaceuticals

The acquisition forms a part of the company’s strategy to become a significant global biopharmaceutical company with drug discovery and clinical development capabilities for generating medicines. With this

The international phase 2/3 clinical trial, which involved Moffitt Cancer Center faculty, demonstrated that Gardasil 9 vaccination can protect against nine HPV types, seven of which cause most

Subutex is a medical treatment of opioid dependence. The company plans to commence deliveries of the product shortly. According to IMS Health data, Subutex had total sales of

Financed through a combination of bank debt and bonds, the acquisition amounts to about $158 for each of Salix’s outstanding shares, and will be followed by a merger

For the NDA, the FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of 11 August 2015. Cobimetinib is a specific MEK inhibitor discovered by

Malaysia is the 20th country to approve the company’s Phase III trial, which has now enrolled more than 350 patients with advanced primary, not yet treated, head and

Currently, Questcor operates as the autoimmune and rare diseases business of Mallinckrodt Pharmaceuticals. In Canada, Synacthen Depot is approved for therapeutic use in patients diagnosed with many difficult-to-treat